Ajanta pharma- share fundamental analysis

4
BSE Code : 532331 NSE Code : AJANTPHARM Sector : PHARMACEUTICALS Report date : Thu Apr 24 06:50:24 EDT 2014 Industry overview Market Cap Market Cap is the price of all the outstanding common shares if we were to buy it all at the current price 3461.29 Cr The benchmark company Sun Pharma in the pharmaceuticals sector is 38 times the size of Ajanta Pharma Mid Caps are a choice for people who can take medium volatility/risk with higher chance of returns 1

Transcript of Ajanta pharma- share fundamental analysis

Page 1: Ajanta pharma- share fundamental analysis

BSE Code : 532331

NSE Code : AJANTPHARM

Sector : PHARMACEUTICALSReport date : Thu Apr 24 06:50:24 EDT 2014

Industry overview

Market CapMarket Cap is the price ofall the outstandingcommon shares if we wereto buy it all at the currentprice

3461.29 Cr

The benchmark companySun Pharma in thepharmaceuticals sector is38 times the size of AjantaPharma

Mid Caps are a choice forpeople who can takemedium volatility/risk withhigher chance of returns

1

Page 2: Ajanta pharma- share fundamental analysis

Stock AnalysisGrowth Analysis

Companies that have grown historically are more likely to exibit similar growth in the future. Read

the trends in the 4 year annualized profit growth, book value growth and sales growth shown

below:

How good are the returns?

RoE is the speed at which the company might grow without sorting to additional fund raising.

RoCE is the growth speed, if the company used all the assets, including loans/preference shares.

The 2-year and 4-year values give a reasonable assurance about the growth sustenance.

KEY

KEY

2

Page 3: Ajanta pharma- share fundamental analysis

Piotroski ScoreSeperate Winners from Losers

The Piotroski scoring system is a nine point system to determine the strength of a firm's financial

position. The score was developed by an accounting professor out of Chicago named Joseph

Piotroski. If it scores an 8 or 9, then the fundamentals are great for the stock.

Score: 8/9

3

Page 4: Ajanta pharma- share fundamental analysis

DISCLAIMER

This report is prepared by the good.inve.story. software and is not prepared by an

actual person who has a CFA or any other certification.

good.inve.story. is still in BETA mode. So, please let us know if you find any errors.

We would love to hear from you.

This report is based on information obtained from public sources and sources

believed to be reliable, but no independent verification has been made nor is its

accuracy or completeness guaranteed.

This report is not an advisory to buy or sell. Please buy only if you think, this is the

right company at the right price and sell only if you don’t see any potential for

upside.

get more @ goodinvestory.com

4